Background Gastrointestinal harm, known to occur with NSAIDs, is thought to be lower with
NSAID and gastroprotective agent, and with inhibitors selective to cyclooxygenase-2 …

Although use of NSAIDs and aspirin (acetylsalicylic acid) is well known to be associated with
gastrointestinal (GI) complications and potential mortality, these medications continue to be …

Network Meta-Analysis Comparing Relatively Selective COX-2 I... : Medicine Network Meta-Analysis
Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced …

ABSTRACT Objective: Cyclo-oxygenase-2 (COX-2) inhibitors rofecoxib and valdecoxib were
withdrawn from the market because of their association with cardiovascular problems. There …

Objective Recently guidelines for the treatment and prevention of ulcers induced by
nonsteroidal anti-inflammatory drugs (NSAIDs) have been established. The aim of the …

Objective A number of drugs used concurrently with non-steroidal anti-inflammatory drugs
(NSAIDs) increase the risk of gastrointestinal (GI) haemorrhage. We studied the prescribing …

Drug use increases with age and the elderly is at increased risk of adverse drug reactions.
Gastrointestinal adverse effects are one of the most often reported. Serious event are mostly …

Background: In 2006 PPI was the third most frequently prescribed drug in Australia. In
United States, UK and New Zealand similar trends were observed. Utilization of proton …

Purpose To explore the effect on prescribing of policies that lift reimbursement restrictions on
selected H2‐antihistamines and proton pump inhibitors (PPI) and of practice …

What is already known about this subject• Public concern regarding the cardiovascular
safety of the COX‐2 inhibitors began with the withdrawal of rofecoxib from the market in …